Table 3.
Subgroup analysis with primary outcome in risk group by continued or discontinued anticoagulants in events (%) per 100 patient years (95% confidence intervals)
Groups | Low risk women* who discontinued oral anticoagulants (n=591) |
---|---|
Age <50 (n=429): | 2.0 (0.8 to 3.9) |
Oestrogen (n=291) | 1.4 (0.4 to 3.7) |
No oestrogen (n=138) | 3.1 (0.8 to 7.9) |
Age ≥50 (n=162): | 5.7 (2.6 to 10.9) |
Oestrogen (n=24) | 0 |
No oestrogen (n=138) | 6.8 (3.1 to 12.8) |
Type of index VTE: | |
Isolated DVT (n=177) | 3.0 (1.0 to 7.0) |
Isolated PE (n=323) | 3.9 (2.0 to 6.8) |
DVT and PE (n=91) | 0 |
Country or region: | |
North America (n=334) | 3.7 (1.9 to 6.6) |
Europe (n=207) | 2.5 (0.1 to 5.9) |
India (n=47) | 0 |
Australia (n=3) | 0 |
Anticoagulant at baseline or enrolment visit: | |
Vitamin K antagonist (n=459) | 2.9 (1.6 to 5.0) |
All non-vitamin K antagonists (n=132) | 3.2 (0.9 to 8.3) |
Known “weak” thrombophilia: | |
Factor V Leiden (n=59) | 3.5 (0.4 to 12.6) |
Prothrombin gene variant (n=26) | 3.9 (0.1 to 21.6) |
VTE=venous thromboembolism; CVT=deep vein thrombosis; PE=pulmonary embolism.
*HERDOO2 criteria: hyperpigmentation, oedema, or redness in either leg at 5-12 months at baseline or enrolment visit, VIDAS D-dimer ≥250 μg/L during anticoagulant treatment, obesity with body mass index ≥30, or older age, ≥65 years. Low risk=0 or 1 of the criteria present.